Albrecht K, et al. - Authors assessed the glucocorticoid (GC) use in patients with polymyalgia rheumatica (PMR), giant cell arteritis (GCA) or both diseases (PMR + GCA) under rheumatological care, using data from the National Database of the German Collaborative Arthritis Centers. In addition, they analyzed related comorbidities (osteoporosis, diabetes, and cardiovascular disease), stratified by disease duration (DD). Only osteoporosis prevalence increased within 3 years out of all examined comorbidities. About one-fourth of all the patients used GC for ≥ 3 years. Within the first year, a difficult-to-control disease activity was a good predictor of long-term GC need.